Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations

Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) have shown promise against non-small cell lung cancers (NSCLCs) in clinics but the utility is often short-lived because of T790M mutations in EGFR that help evade TKIs’ action. Osimertinib is the third and latest generation TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiao-Feng, Shen, Wei-Zhang, Jin, Xin, Ren, Ping, Zhang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343825/
https://www.ncbi.nlm.nih.gov/pubmed/32641854
http://dx.doi.org/10.1038/s41598-020-67908-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343825/
https://www.ncbi.nlm.nih.gov/pubmed/32641854
http://dx.doi.org/10.1038/s41598-020-67908-4

Ejemplares similares